AMPH projects ongoing remediation expenses while reaffirming mid-to-high single-digit sales growth for 2026.
Amphastar Pharmaceuticals expects to incur $2M to $3M in quarterly costs to address IMS remediation efforts. The company reported Q2 2026 revenue of approximately $184, citing strong execution across growth initiatives.
Management maintained its outlook for mid-single digit to high single-digit sales growth in 2026. The projected remediation costs follow prior operational adjustments but are not expected to derail broader growth targets.
No immediate market reaction was disclosed in the earnings call summary.